Search Results - "Türeci, Ö." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

by Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J.W., Schuler, M., Al-Batran, S.-E.
Published in Annals of oncology (01.05.2021)

Get full text

Journal Article

A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer

A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer

by Reppert, S., Boross, I., Koslowski, M., Türeci, Ö., Koch, S., Lehr, H.A., Finotto, S.
Published in Nature communications (20.12.2011)

Get full text

Journal Article

$A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study$

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

by Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., Schuler, M.
Published in Annals of oncology (01.09.2019)

Get full text

Journal Article

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

by Boisguérin, V, Castle, J C, Loewer, M, Diekmann, J, Mueller, F, Britten, C M, Kreiter, S, Türeci, Ö, Sahin, U
Published in British journal of cancer (14.10.2014)

Get full text

Journal Article

1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

by Forde, P.M., Atmaca, A., Brück, P., Munshi, N., Kaczorowska, M.A., Schell, T., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)

658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)

by Morlock, R, Krukas-Hampel, M R, Türeci, Ö
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

999MO HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma

999MO HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma

by Ottensmeier, C.H.H., King, E., Crabb, S., Karydis, I., Graham, D.M., Martin, K., Eberhart, I., Ewings, S., Lee, P., McCann, K., Chudley, L., Berry, L., Dias, J., Das, R., Furlanetto, J., Johnson, E., Setzer, J., Sahin, U., Türeci, Ö., Griffiths, G.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate

Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate

by Kreuzberg, M., Mitnacht-Kraus, R., Sahin, U., Türeci, Ö.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article

1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models

1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models

by Fellermeier-Kopf, S., Ioan-Facsinay, A., Imle, A., Diks, A.M., Nuermberger, K.B., Guelen, L., Köhne, M., Houtkamp, M., Toker, A., Burm, S.M., Gamse, J., Janaitis, C., Satijn, D., Muik, A., Ahmadi, T., Türeci, Ö., Kemper, K., Sahin, U., Breij, E.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)

LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)

by Mackensen, A., Haanen, J.B.A.G., Alsdorf, W., Koenecke, C., Wagner-Drouet, E., Borchmann, P., Heudobler, D., Busse, A., Klobuch, S., Kutsch, N., Müller, F., Bokemeyer, C., Desuki, A., Lueke, F., Ho, T., Vemuri, K., Preussner, L., Rengstl, B., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

$611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors$

611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors

by Haanen, J.B.A.G., Mackensen, A., Schultze-Florey, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Busse, A., Mielke, S., Bins, S., Ungerechts, G., Bokemeyer, C., Klobuch, S., Kutsch, N., Müller, F., Desuki, A., Zhong, W., Preussner, L., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC

877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC

by Saba, N.F., Klinghammer, K., Castelluci, E., Colevas, A.D., Rutkowski, T., Thurner, D., Müller-Richter, U., Maio, M., Grewal, J.S., Ottensmeier, C.H.H., Dias, J., Yang, H., Das, R., Furlanetto, J., Herzfeldt, A-K., Kühnle, M-C., Ulges, A., Alles, J., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial

29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial

by Elez Fernandez, M.E., Maurel, J., Morris, V., Kopetz, S., Galligan, B., Ali, S., Derhovanessian, E., Unsal-Kacmaz, K., Manning, L., Henn, H., Weisenburger, T., Tonigold, M., Zurek, P., Fierek-Ulbig, M., Cortini, A., Pino Claveria, M., Preussner, L., Mueller, F., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.06.2024)

Get full text

Journal Article

Molecular characterization of virus-induced autoantibody responses

Molecular characterization of virus-induced autoantibody responses

by Krebs, P, Ludewig, B, Metters, Türeci, Ö, Sahin, U
Published in Cancer cell international (01.07.2004)

Get full text

Journal Article

LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors

LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors

by Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preußner, L., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.12.2021)

Get full text

Journal Article

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

by Kuhn, A N, Diken, M, Kreiter, S, Selmi, A, Kowalska, J, Jemielity, J, Darzynkiewicz, E, Huber, C, Türeci, Ö, Sahin, U
Published in Gene therapy (01.08.2010)

Get full text

Journal Article

1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine

1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine

by Thomas, S.J., Perez, J.L., Lockhart, S.P., Hariharan, S., Kitchin, N., Bailey, R., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., Xu, X., Dychter, S.S., Lu, C., Gentile, T., Gruber, W.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

Preclinical characterization of IMAB362 for the treatment of gastric carcinoma

Preclinical characterization of IMAB362 for the treatment of gastric carcinoma

by Mitnacht-Kraus, R., Kreuzberg, M., Utsch, M., Sahin, U., Türeci, Ö.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article

Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma

Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma

by Heinz, C., Mitnacht-Kraus, R., Kreuzberg, M., Wöll, S., Sahin, U., Türeci, Ö.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article

First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer

First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer

by Sahin, U., Schuler, M., Bauer, S., Krilova, A., Utsch, M., Huber, C., Türeci, Ö.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article